Dechra acquires Gallant to enter regenerative veterinary medicine
The deal adds Gallant's mesenchymal stromal cell therapies for chronic and complex conditions in pets to Dechra's global commercial reach.
See the latest news and media coverage for Dechra. We track all announcements, press releases, and industry mentions in real time, all in one place.
Veterinary pharmaceutical and animal health products company
dechra.comLast updated
In short: Dechra completed Gallant Pet acquisition, adding cell therapies with a first product anticipated as early as 2027.
The deal adds Gallant's mesenchymal stromal cell therapies for chronic and complex conditions in pets to Dechra's global commercial reach.
The U.S. animal health biotechnology company develops off-the-shelf mesenchymal stromal cell therapies for pets, supporting Dechra's specialty care strategy. Terms stay confidential pending closing conditions.
The East Windsor site will create over 100 full-time jobs over the next decade and is expected to be fully operational in 2028.
The report highlights progress in sustainable innovation, a 27% cut in Scope 1 and 2 emissions since baseline, and 98% of waste recycled, reused or recovered.
Dechra, a global leader in veterinary specialty care, today completed its acquisition of Gallant Pet Inc (Gallant), a U.S.-based animal...
Veterinary pharmaceuticals group Dechra (DPH) has backed a £4.5bn buyout by the Swedish private equity firm EQT. The board has recommended the offer of 3,875p...
Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. Veterinary pharmaceuticals company Dechra has agreed a £4.5bn buyout by Sweden’s...
Dechra Pharmaceuticals has confirmed they have entered into discussions to be acquired by Swedish private equity firm EQT for £4.6bn. Under the terms of the...
Track Dechra and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Dechra and other trending companies.